Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Patient compliance with drug therapy for diabetic nephropathy

William F. Clark and Lorie Forwel
CMAJ May 30, 2000 162 (11) 1553-1554;
William F. Clark
Division of Nephrology London Health Sciences Centre London, Ont. Department of Physiotherapy University of Western Ontario London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorie Forwel
Division of Nephrology London Health Sciences Centre London, Ont. Department of Physiotherapy University of Western Ontario London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Dyfrig Hughes and Braden Manns suggest that there are 3 important assumptions regarding compliance that require further clarification in our decision and cost-utility analysis.1

First, we assumed that noncompliers lose renal function at the same rate as patients in the placebo arm of a diabetic nephropathy trial.2 We selected 80% adherence as the threshold required for antihypertensive drug effect on the basis of studies3,4,5,6 we referenced in our article.1 However, some degree of renoprotection may still occur at adherence levels below 80%, as the renoprotective effects of the drug therapy may be independent of the blood pressure effects in this particular disease. Therefore, we do concur that a sensitivity analysis could have been carried out.

Second, Hughes and Manns question whether cost really is the primary barrier for drug adherence for 34% of patients. This assumption is based on a Canadian study that indicated that 34% of the compliance failure was due to cost, representing 17% of patients.7 We indicated in our article that this was a conservative estimate, as price elasticity has been demonstrated to be as high as 64% in a large randomized controlled study and a very large population study.8,9 We would contend that the figure we used describing the relationship between drug cost and adherence is conservative. Hughes and Manns also indicate that the relationship was less clear in view of a study by Caro and colleagues that looked at patients in Saskatchewan between 1989 and 1994.10 They may not be aware that in Saskatchewan during that time period there was a fairly comprehensive pharmacare program, which might explain variations between expensive and inexpensive antihypertensive agents.11 However, we agree that factors other than drug costs must not be ignored when evaluating the implications of noncompliance.

Finally, we feel that our assumption concerning the proportion of patients already being covered through provincial or private insurance is valid. We concur with Hughes and Manns that the effect on adherence of providing medications free at the point of delivery should be more thoroughly assessed. We also hope that if such studies are undertaken and do show significant improvements in adherence, there would be consideration to developing a national pharmacare program whereby cost-effective medications such as ACE inhibitors for diabetic nephropathy would be provided free to all Canadians.

Competing interests: See original article.1

References

  1. 1.↵
    Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000;162(2):195-8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 11-23.
  4. 4.↵
    Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68.
    OpenUrl
  5. 5.↵
    Gibaldi M. Failure to comply: a therapeutic dilemma and the bane of clinical trials. J Clin Pharmacol 1996;36:674-82.
    OpenUrlCrossRefPubMed
  6. 6.↵
    McKenney JM, Munroe WP, Wright JT. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol 1992;32:277-83.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Brand FN, Smith RT, Brand PA. Effect of economic barriers to medical care on patients' noncompliance. Public Health Rep 1977;92:72-8.
    OpenUrlPubMed
  8. 8.↵
    Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med 1985;21:1063-9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    O'Brien B. The effect of patient charges on the utilisation of prescription medicines. J Health Econ 1989;8:109-32.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160(1):41-6.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160(1):31-7.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 11
30 May 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Patient compliance with drug therapy for diabetic nephropathy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Patient compliance with drug therapy for diabetic nephropathy
William F. Clark, Lorie Forwel
CMAJ May 2000, 162 (11) 1553-1554;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Patient compliance with drug therapy for diabetic nephropathy
William F. Clark, Lorie Forwel
CMAJ May 2000, 162 (11) 1553-1554;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire